| 1.95 0.02 (1.04%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.69  |
1-year : | 4.66 |
| Resists | First : | 3.16 |
Second : | 3.99 |
| Pivot price | 2.3 |
|||
| Supports | First : | 1.82 | Second : | 1.51 |
| MAs | MA(5) : | 2.09 |
MA(20) : | 2.48 |
| MA(100) : | 3.49 |
MA(250) : | 6.05 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 15 |
| RSI | RSI(14): 38.8  |
|||
| 52-week | High : | 17.68 | Low : | 1.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SXTP ] has closed above bottom band by 28.2%. Bollinger Bands are 18.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.96 - 1.97 | 1.97 - 1.98 |
| Low: | 1.84 - 1.86 | 1.86 - 1.87 |
| Close: | 1.93 - 1.95 | 1.95 - 1.97 |
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
Sat, 21 Mar 2026
60 Degrees Pharmaceuticals, Inc. Corrects Prospectus Supplement Disclosure in SEC Form 8-K Filing (March 20, 2026) - Minichart
Fri, 20 Mar 2026
60 Degrees Updates Affiliate Share Ownership Disclosure Error - TipRanks
Fri, 20 Mar 2026
60 Degrees Pharmaceuticals corrects affiliate share counts in prospectus supplement - TradingView
Fri, 20 Mar 2026
Affiliate share ownership restated by 60 Degrees (NASDAQ: SXTP) - Stock Titan
Wed, 18 Mar 2026
60 Degrees Pharma submits dietary supplement notification to FDA - Investing.com
Wed, 18 Mar 2026
Australian chestnut extract faces FDA review before US supplement launch - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 107 (K) |
| Shares Short P.Month | 62 (K) |
| EPS | -3.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -5.02 |
| Profit Margin | 0 % |
| Operating Margin | -440 % |
| Return on Assets (ttm) | -70.1 % |
| Return on Equity (ttm) | -154.8 % |
| Qtrly Rev. Growth | 256.8 % |
| Gross Profit (p.s.) | 0.45 |
| Sales Per Share | 1.05 |
| EBITDA (p.s.) | -6.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | 0 |
| Price to Book value | -0.39 |
| Price to Sales | 1.84 |
| Price to Cash Flow | -0.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|